EMD Malaria Day Seminar: Peter Crompton, "Clinical Development of Monoclonal Antibodies against Malaria in Africa"

New tools are needed to reduce malaria morbidity and mortality in the highest risk populations including infants, children, and pregnant women. Recent early phase clinical trials have highlighted the potential utility of anti-sporozoite monoclonal antibodies in preventing P. falciparum infection for defined time periods in high-risk populations. This presentation will summarize the clinical development of the anti-sporozoite monoclonal antibodies CIS43LS and L9LS in Africa.

YSPH values inclusion and access for all participants.

If you have questions about accessibility or would like to request an accommodation, please contact Maria Reilly at maria.reilly@yale.edu.